PDS Biotechnology (PDSB) Competitors $1.25 -0.07 (-4.92%) As of 02:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB vs. OCGN, AMRN, BTMD, SOPH, TERN, CRDF, GOSS, DSGN, TVGN, and HURAShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Ocugen (OCGN), Amarin (AMRN), biote (BTMD), SOPHiA GENETICS (SOPH), Terns Pharmaceuticals (TERN), Cardiff Oncology (CRDF), Gossamer Bio (GOSS), Design Therapeutics (DSGN), Tevogen Bio (TVGN), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. Ocugen Amarin biote SOPHiA GENETICS Terns Pharmaceuticals Cardiff Oncology Gossamer Bio Design Therapeutics Tevogen Bio TuHURA Biosciences Ocugen (NASDAQ:OCGN) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Does the media prefer OCGN or PDSB? In the previous week, PDS Biotechnology had 3 more articles in the media than Ocugen. MarketBeat recorded 4 mentions for PDS Biotechnology and 1 mentions for Ocugen. PDS Biotechnology's average media sentiment score of 0.94 beat Ocugen's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of OCGN or PDSB? 10.3% of Ocugen shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 4.3% of Ocugen shares are held by company insiders. Comparatively, 9.5% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate OCGN or PDSB? Ocugen presently has a consensus price target of $6.33, indicating a potential upside of 780.85%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 617.13%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk & volatility, OCGN or PDSB? Ocugen has a beta of 3.78, suggesting that its share price is 278% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Which has better valuation and earnings, OCGN or PDSB? PDS Biotechnology has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.06M51.78-$63.08M-$0.19-3.78PDS BiotechnologyN/AN/A-$42.94M-$1.03-1.22 Is OCGN or PDSB more profitable? PDS Biotechnology has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. PDS Biotechnology's return on equity of -139.57% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-532.51% -154.75% -90.79% PDS Biotechnology N/A -139.57%-67.22% Does the MarketBeat Community believe in OCGN or PDSB? Ocugen received 38 more outperform votes than PDS Biotechnology when rated by MarketBeat users. Likewise, 71.07% of users gave Ocugen an outperform vote while only 70.75% of users gave PDS Biotechnology an outperform vote. CompanyUnderperformOutperformOcugenOutperform Votes11371.07% Underperform Votes4628.93% PDS BiotechnologyOutperform Votes7570.75% Underperform Votes3129.25% SummaryPDS Biotechnology beats Ocugen on 11 of the 17 factors compared between the two stocks. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.20M$6.63B$5.42B$7.75BDividend YieldN/A3.20%5.44%4.31%P/E Ratio-1.097.1322.2118.28Price / SalesN/A238.37389.19101.44Price / CashN/A65.6738.2034.62Price / Book1.496.256.644.16Net Income-$42.94M$142.48M$3.21B$247.58M7 Day Performance16.20%7.49%5.30%5.88%1 Month Performance-4.92%-6.38%-4.77%-3.60%1 Year Performance-61.50%-1.20%17.34%4.86% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology1.8225 of 5 stars$1.26-4.9%$9.00+617.1%-59.4%$57.20MN/A-1.0920Analyst RevisionOCGNOcugen0.809 of 5 stars$0.67-2.8%$6.33+843.4%-37.6%$196.03M$4.06M-3.7380AMRNAmarin0.2419 of 5 stars$9.47+1.8%N/A-36.4%$194.46M$228.61M-105.22360Analyst RevisionHigh Trading VolumeBTMDbiote3.1141 of 5 stars$3.53-3.3%$8.00+126.6%-38.3%$193.13M$197.19M13.58194Positive NewsSOPHSOPHiA GENETICS1.406 of 5 stars$2.89+0.3%$6.80+135.3%-39.7%$192.73M$65.17M-2.65520TERNTerns Pharmaceuticals4.1377 of 5 stars$2.31+7.9%$18.38+695.5%-35.8%$186.82MN/A-1.9640News CoveragePositive NewsCRDFCardiff Oncology1.0404 of 5 stars$2.79+13.0%$11.67+318.2%-30.6%$185.60M$683,000.00-2.9720Upcoming EarningsNews CoverageGOSSGossamer Bio3.7682 of 5 stars$0.81-1.5%$7.75+853.4%+38.2%$184.71M$114.70M-2.54180DSGNDesign Therapeutics1.6499 of 5 stars$3.25+12.5%$8.00+146.2%+16.2%$184.48MN/A-3.8240News CoverageTVGNTevogen Bio3.7114 of 5 stars$1.05-2.8%$7.10+576.2%-32.7%$183.80MN/A0.003HURATuHURA BiosciencesN/A$4.20-0.5%$12.67+201.6%N/A$183.46MN/A0.00N/AGap Down Related Companies and Tools Related Companies OCGN Competitors AMRN Competitors BTMD Competitors SOPH Competitors TERN Competitors CRDF Competitors GOSS Competitors DSGN Competitors TVGN Competitors HURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDSB) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
